STOCKHOLM, Aug. 21,
2024 /PRNewswire/ --
January 1 - June 30,
2024
The second quarter in figures
- Net sales were TSEK 6,641 (5,085), +31%.
- The loss after tax was TSEK 15,050 (11,352).
- The loss per share was SEK 0.08 (0.16).
- The cash flow from current operations was negative in the
amount of TSEK 15,179 (13,054).
- The gross margin was 69.1% (65.3%).
- Electrode sales volume increased by 24% and was 14,106 (11,330)
units. Repeat sales of electrodes to existing customers increased
by 22%.
January - June in
figures
- Net sales were TSEK 12,699 (10,234), +24%.
- The loss after tax was TSEK 25,911 (22,258).
- The loss per share was SEK 0.19 (0.31).
- The cash flow from current operations was negative in the
amount of TSEK 28,360 (16,805).
- The gross margin was 69.5% (67.0%).
- Electrode sales volume increased by 21% and was 27,868 (22,944)
units. Repeat sales of electrodes to existing customers increased
by 23%.
Important events during the quarter
- Overall sales increased by 31% (+30, before currency effects).
Sales in Germany within the skin
cancer segment increased by 12% (11% in local currency).
Sales in the US skin cancer market increased by 468% while
the sales within the skin barrier segment increased by 7%.
- SciBase resolved on a directed issued of approximately
SEK 33 million and a rights issue of
approximately SEK 15 million and
postponed the Annual General Meeting and publication of the interim
report for the first quarter of 2024.
- SciBase published a prospectus and the summons to an EGM and
the AGM.
- SciBase announced a new partnership with Al Shirawi Healthcare
solutions for the distribution of Nevisense in the UAE.
- SciBase published the outcomes in the directed issue, were MSEK
33 were subscribed for and in the rights offering were MSEK were
subscribed for corresponding to a subscription rate of 61%.
- New German study shows Nevisense significantly improves
dermatologists' clinical decisions.
- SciBase launched the eBarrier Score, the First AI-Driven Skin
Barrier Assessment tool for research and Cosmetic Testing.
- SciBase received the first order in Austria.
- US organization strengthened with experienced leader in
dermatology.
- Partnership established with a large health care group in
Los Angeles, Unified Health, and
SciBase receives a first order.
- The AGM was held on June
13th, new chairman of the Board appointed.
Important events after the end of the period
- No events of significant nature have occurred after the end of
the period.
Financial overview
|
|
|
|
|
July 1, 2023
-
|
|
|
Apr 1 - June
30
|
Jan 1 - June
30
|
June 30,
2024
|
Jan 1 - Dec
31
|
|
THE
GROUP
|
2024
|
2023
|
2024
|
2023
|
Rolling-12
|
2023
|
|
Net sales, SEK
ths
|
6 641
|
5 085
|
12 699
|
10 234
|
25 710
|
23 245
|
|
Gross margin,
%
|
69.1 %
|
65.3 %
|
69.5 %
|
67.0 %
|
70.0 %
|
69.0 %
|
|
Equity/Asset ratio,
%
|
71.8 %
|
73.7 %
|
71.8 %
|
73.7 %
|
72.9 %
|
66.9 %
|
|
Net indebtness,
multiple
|
0.39
|
0.36
|
0.39
|
0.36
|
0.37
|
0.49
|
|
Cash equivalents, SEK
ths
|
43 271
|
70 874
|
43 271
|
70 874
|
43 271
|
34 121
|
|
Cashflow from operating
activities, SEK ths
|
-15 179
|
-13 054
|
-28 360
|
-16 805
|
-63 539
|
-51 984
|
|
Earnings per share
(before and after dilution), SEK
|
-0.08
|
-0.16
|
-0.19
|
-0.31
|
-0.46
|
-0.51
|
|
Shareholder's equity
per share, SEK
|
0.28
|
0.60
|
0.39
|
0.75
|
0.49
|
0.40
|
|
Average number of
shares, 000'
|
186 303
|
119 831
|
136 449
|
96 129
|
128 140
|
107 980
|
|
Number of shares at
closing of period, 000'*
|
219 538
|
119 831
|
219 538
|
119 831
|
219 538
|
119 831
|
|
Share price at end of
period, SEK
|
0.51
|
1.19
|
0.51
|
1.19
|
0.51
|
0.83
|
|
Number of sold
electrodes, pieces
|
14 016
|
11 330
|
27 868
|
22 944
|
56 844
|
51 920
|
|
Average number of
employees
|
27
|
22
|
27
|
21
|
26
|
23
|
This information is information that SciBase
Holding AB is obliged to make public pursuant to the EU Market
Abuse Regulation. The information was submitted for publication,
through the agency of the contact person set out below, at 08.00
CET on August 21, 2024.
This interim report report has not been subject
to review by the Company's auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For more information, please contact: Pia Renaudin,
CEO SciBase Tel: +46 73 206 98 02
Email: pia.renaudin@scibase.com
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About SciBase
SciBase is a global medical technology company, specializing
in early detection and prevention in dermatology. SciBase develops
and commercializes Nevisense, a unique point-of-care platform that
combines AI (artificial intelligence) and advanced EIS technology
to elevate diagnostic accuracy, ensuring proactive skin health
management.
Our commitment is to minimize patient suffering, allowing
clinicians to improve and save lives through timely detection and
intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in
dermatological advancements.
The company has been on the Nasdaq First North Growth Market
exchange since June 2, 2015. Learn
more at www.scibase.com. All press
releases and financial reports can be found
here: http://investors.scibase.se/en/pressreleases
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/interim-report,c4026577
The following files are available for download:
|
https://mb.cision.com/Main/12371/4026577/2953491.pdf
|
Interim report Q2 2024
- final
|
View original
content:https://www.prnewswire.co.uk/news-releases/interim-report--scibase-302227232.html